ACLX News and Press, Arcellx Inc. From 12/09/22

Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress PR Newswire -- 100% ORR at both CART-ddBCMA dose levels; deep and durable responses o...

-- Collaboration Leverages Expertise Across Both Companies, Including Kite’s Global Cell Therapy Leadership and Industry Leading Reliable Manufacturing -- Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to ...

Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma PR Newswire -- Collaboration leverages expertise across both companies, including Kite's global cell therapy leadership and industry leading...

Arcellx press release ( NASDAQ: ACLX ): Q3 GAAP EPS of -$2.12. As of September 30, 2022, Arcellx had cash, cash equivalents, and marketable securities of $280.8 million, which is anticipated to fund its operations for at least the next 12 months. For further details ...

Arcellx Reports Third Quarter 2022 Financial Results and Business Progress PR Newswire -- Initiated iMMagine-1 Phase 2 pivotal study for CART-ddBCMA  -- -- Longer-term follow-up patient data from the Phase 1 CART-ddBCMA expansion trial will be presented at the 6...

The following slide deck was published by Arcellx, Inc. in conjunction with this event. For further details see: Arcellx (ACLX) Corporate Presentation - Slideshow

Summary Shares have lost over 40% of their value since the spinoff in November. The pipeline has multiple shots on goal including in solid tumors and AML plus validating partnerships via Regeneron and BMY. A successful interim readout for its KARMA-3 study sped up the clinical...

Summary Arcellx shares have risen by 20% since February IPO and are up 131% over the past 3 months. Arcellx's novel synthetic binding scaffold (D-Domain) is designed to overcome limitations of traditional CAR-Ts. Data shared in June for CART-ddBCMA in r/r multiple myeloma show...

Arcellx produced strong data in a traditional CAR-T product. However, its core USP is its SparX technology. This data will be out sometime next year. I covered Arcellx ( ACLX ) at its IPO in January. Arcellx is a clinical stage biopharma developing cancer immunothera...

Arcellx press release ( NASDAQ: ACLX ): Q2 GAAP EPS of -$0.88. cash, cash equivalents, and marketable securities of $307.0 million For further details see: Arcellx GAAP EPS of -$0.88